These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7968752)

  • 21. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
    Singh N; Mironov D; Armstrong PW; Ross AM; Langer A
    Circulation; 1996 Apr; 93(7):1388-95. PubMed ID: 8641028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative assessment of efficacy of tissue plasminogen activator and streptokinase in the treatment of patients with acute myocardial infarction].
    Shul'man VA; Radionov VV; Golovenkin SE; Pediashov VE; Linev KA; Titarenko OM; Simulin VN; Pasal'skiĭ VL; Peterson LS; Necheporenko GI; Kononova LI; Peterson EV
    Kardiologiia; 2004; 44(5):40-2. PubMed ID: 15159721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial].
    Steffensen R; Sandøe E
    Ugeskr Laeger; 1991 Oct; 153(41):2880-3. PubMed ID: 1949301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adhesion molecules in different treatments of acute myocardial infarction.
    Kerner T; Ahlers O; Reschreiter H; Bührer C; Möckel M; Gerlach H
    Crit Care; 2001; 5(3):145-50. PubMed ID: 11353931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
    Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A comparative evaluation between streptokinase and r-TPA in limiting the myocardial damage during an acute myocardial infarct. An echocardiographic study].
    Morelloni S; Fasciolo L; Freggiaro V; Corazza M; Pareti G; Davi R; Allegri M
    Clin Ter; 1990 Dec; 135(5):359-65. PubMed ID: 2150366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Mak KH; Moliterno DJ; Granger CB; Miller DP; White HD; Wilcox RG; Califf RM; Topol EJ
    J Am Coll Cardiol; 1997 Jul; 30(1):171-9. PubMed ID: 9207639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial).
    Barbagelata A; Califf RM; Sgarbossa EB; Goodman SG; Knight D; Mark DB; Granger CB; Agranatti DA; Mautner B; Ohman EM; Suárez LD; Armstrong PW; Gates K; Wagner GS
    Am J Cardiol; 2000 Jul; 86(1):24-9. PubMed ID: 10867087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy.
    Brody B; Wray N; Bame S; Ashton C; Petersen N; Harward M
    Med Care; 1991 Sep; 29(9):899-910. PubMed ID: 1921539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; White HD; Modan M; Diaz R; Hampton JR; Heikkila J; Kristinsson A; Moulopoulos S; Paolasso EA; Van der Werf T
    Arch Intern Med; 1994 Oct; 154(19):2237-42. PubMed ID: 7944845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
    Naylor CD; Armstrong PW
    CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
    Peuhkurinen K; Risteli L; Jounela A; Risteli J
    Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals].
    Andreassen AK; Gullestad L; Endresen K
    Tidsskr Nor Laegeforen; 1998 Jun; 118(17):2630-1. PubMed ID: 9673511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
    Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
    Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.